We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

57 hedge funds and large institutions have $223M invested in Krystal Biotech in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

73% more capital invested

Capital invested by funds: $129M → $223M (+$94.1M)

27% more funds holding

Funds holding: 45 → 57 (+12)

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

3.51% more ownership

Funds ownership: 43.03% → 46.53% (+3.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
57
Holders Change
+12
Holders Change %
+26.67%
% of All Funds
1.23%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
17
Increased
19
Reduced
16
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$2.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.98M
3
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC)
Nebraska
+$1.46M
4
O
OrbiMed
New York
+$1.4M
5
ECM
Endurant Capital Management
California
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
-$2.12M
2
Invesco
Invesco
Georgia
-$979K
3
NIP
Nicholas Investment Partners
California
-$466K
4
Citadel Advisors
Citadel Advisors
Florida
-$287K
5
Renaissance Technologies
Renaissance Technologies
New York
-$262K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$40.6M – – –
FM
2
Frazier Management
Washington
$28.8M – – –
BBA
3
Baker Bros. Advisors
New York
$25.8M – – –
GPP
4
Great Point Partners
Connecticut
$16.2M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$11.6M +$394K +16,705 +5%
RG
6
Redmile Group
California
$10.7M -$11.8K -500 -0.2%
Citadel Advisors
7
Citadel Advisors
Florida
$10.6M -$287K -12,155 -4%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$10M +$14.1K +600 +0.2%
AG
9
Artal Group
Luxembourg
$9.87M +$589K +25,000 +9%
KCM
10
Knoll Capital Management
Florida
$6.91M -$2.12M -90,014 -30%
SFM
11
Sphera Funds Management
Israel
$5.97M +$165K +7,000 +4%
Carson Wealth (CWM LLC)
12
Carson Wealth (CWM LLC)
Nebraska
$4.22M +$1.46M +62,112 New
NIP
13
Nicholas Investment Partners
California
$3.66M -$466K -19,751 -15%
Millennium Management
14
Millennium Management
New York
$2.93M +$2.1M +89,155 New
Point72 Asset Management
15
Point72 Asset Management
Connecticut
$2.77M +$1.98M +84,084 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.36M +$262K +11,095 +18%
SST
17
S Squared Technology
New York
$2.27M -$118K -5,000 -7%
William Blair & Company
18
William Blair & Company
Illinois
$2.18M +$1.05M +44,426 +204%
ECM
19
Endurant Capital Management
California
$2.01M +$1.15M +48,655 +389%
O
20
OrbiMed
New York
$1.95M +$1.4M +59,210 New
BlackRock
21
BlackRock
New York
$1.82M +$850K +36,040 +188%
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$1.5M +$632K +26,796 +143%
LCM
23
Laurion Capital Management
New York
$1.23M +$476K +20,213 +118%
Barclays
24
Barclays
United Kingdom
$1.18M -$33.1K -1,403 -4%
Allianz Asset Management
25
Allianz Asset Management
Germany
$1.16M +$831K +35,255 New
1
2 3

KRYS Hedge Fund Activity: Q1 2019 in Review

57 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q1 2019, worth a combined $223M — up 73% from $129M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KRYS positions and 5 closed out — a net gain of 12 holders — while 19 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $2.1M. The largest seller was Knoll Capital Management, cutting an estimated $2.12M.

  • 57 institutional investors held Krystal Biotech (KRYS) as of Q1 2019, up from 45 in Q4 2018.
  • Funds reported $223M of Krystal Biotech stock for Q1 2019, up 73% quarter-over-quarter.
  • 17 funds opened new Krystal Biotech positions in Q1 2019 and 5 closed out, a net change of +12 holders.
  • The largest Krystal Biotech buyer in Q1 2019 was Millennium Management, an estimated $2.1M added.
  • The largest Krystal Biotech seller in Q1 2019 was Knoll Capital Management, an estimated $2.12M sold.

Based on aggregated 13F filings for Q1 2019.